文献速递青光眼

DPP-4抑制剂通过抑制TGF-β/Smad信号通路减轻青光眼滤过术后纤维化

DPP-4 Inhibitors Attenuate Fibrosis After Glaucoma Filtering Surgery by Suppressing the TGF-β/Smad Signaling Pathway.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

回顾性分析35例糖尿病合并新生血管性青光眼患者41眼首次小梁切除术,接受DPP-4i治疗者23眼、未接受者18眼,DPP-4i组滤过泡存活Kaplan-Meier曲线更高(P=0.017,log-rank检验)。体外实验显示利格列汀减轻TGF-β1诱导的人Tenon囊成纤维细胞纤维化标志物升高、迁移和胶原凝胶收缩,并抑制Smad2和Smad3磷酸化。

要点

  • 糖尿病合并新生血管性青光眼患者中,接受DPP-4i者滤过泡存活曲线高于未接受者(P=0.017,log-rank检验)。
  • 利格列汀减轻TGF-β1诱导的人Tenon囊成纤维细胞纤维化标志物(α-SMA、Iα型胶原、纤连蛋白)升高。
  • 利格列汀抑制人Tenon囊成纤维细胞Smad2和Smad3磷酸化,即TGF-β信号通路的经典途径。

核心结论

  • 本研究提示DPP-4i对糖尿病合并新生血管性青光眼患者青光眼滤过术后维持滤过泡功能具有潜在作用。
  • 利格列汀通过抑制TGF-β/Smad信号通路减轻人Tenon囊成纤维细胞的纤维化改变。

研究设计与样本

  • 回顾性 Review 了35例糖尿病合并新生血管性青光眼患者41眼的病历,均为接受首次小梁切除术者。
  • 比较接受DPP-4i治疗(n=23)与未接受DPP-4i治疗(n=18)糖尿病患者的的手术成功率。
  • 体外实验用TGF-β1诱导原代人Tenon囊成纤维细胞纤维化,评估利格列汀(一种DPP-4i)的抗纤维化作用。

主要发现

  • 滤过泡存活的Kaplan-Meier曲线在接受DPP-4i的患者中更高(P=0.017,log-rank检验)。
  • 体外实验显示利格列汀减轻TGF-β1诱导的人Tenon囊成纤维细胞纤维化标志物(α-平滑肌肌动蛋白、Iα型胶原、纤连蛋白)水平升高。
  • 利格列汀处理还阻止人Tenon囊成纤维细胞的迁移和凝胶收缩。
  • 利格列汀抑制Smad2和Smad3的磷酸化,即TGF-β信号通路的经典途径。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性病历复习。
  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study investigated the effect of dipeptidyl peptidase-4 inhibitors (DPP-4is) on fibrosis after glaucoma filtering surgery with clinical data and an in vitro model that used transforming growth factor-β (TGF-β) to induce human Tenon's fibroblast (HTF) fibrosis. METHODS: The medical records of 41 eyes of 35 patients with diabetes with neovascular glaucoma (NVG) who received initial trabeculectomy were retrospectively reviewed. The surgical success rate was compared between cases that received (n = 23) and did not receive (n = 18) DPP-4i treatment for diabetes. The antifibrotic effects of linagliptin (a DPP-4i) were evaluated with quantitative real-time PCR for fibrosis markers (α-smooth muscle actin, collagen Iα, and fibronectin), a scratch assay, and a collagen gel contraction assay of primary cultured HTFs treated with TGF-β1 and linagliptin. Western blotting analysis was performed to evaluate the levels of phosphorylated Smad2 and Smad3 in the presence of linagliptin. RESULTS: The Kaplan-Meier curve for bleb survival was higher in patients who received DPP-4is (P = 0.017, log-rank test). The in vitro experiments demonstrated that treatment with linagliptin attenuated the elevated levels of fibrosis markers induced by TGF-β1 in HTFs. Linagliptin treatment also prevented the migration and gel contraction of HTFs. Linagliptin inhibited the phosphorylation of Smad2 and Smad3, which is the canonical pathway of TGF-β signaling. CONCLUSIONS: The current study indicates the potential effect of DPP-4is for maintaining bleb function after glaucoma filtering surgery in patients with diabetes with NVG. Our results demonstrate that linagliptin attenuates fibrotic change in HTFs by inhibiting TGF-β/Smad signaling.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Yoshida M, Kokubun T, Sato K, et al. DPP-4 Inhibitors Attenuate Fibrosis After Glaucoma Filtering Surgery by Suppressing the TGF-β/Smad Signaling Pathway. Invest Ophthalmol Vis Sci. 2023. PMID: 37405760. doi:10.1167/iovs.64.10.2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。